Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sipuleucel-T

- PMLiVE

NICE rejects Roche’s Kadcyla as “unaffordable”

Cancer drug unable to justify £90,000 price tag

National Institute for Health and Care Excellence NICE logo

NICE backs two cancer drugs

Boehringer’s Giotrif and Janssen’s Velcade given final go-ahead for NHS use

- PMLiVE

Pfizer set to file Xeljanz for psoriasis

Set to add another indication after positive study results

- PMLiVE

Pfizer rumoured to be after AstraZeneca

Is this the return of the pharma mega-merger?

National Institute for Health and Care Excellence NICE logo

NICE gives partial backing to Ferring’s prostate cancer drug

Firmagon on course for use on NHS in England and Wales

- PMLiVE

Pfizer’s Emms takes up ABPI presidency

He succeeds MSD’s Deepak Khanna at the UK pharma industry body

- PMLiVE

Pfizer’s breast cancer drug palbociclib extends survival

Positive trial results for oncology treatment

- PMLiVE

Pfizer appoints comms head in Spain

Monica Piñuela is promoted

Roche - Basel

NICE reverses decision to restrict Tarceva access

Roche says “voices of clinicians and patients have been heard”

- PMLiVE

Merck KGaA and Pfizer collaborate on lupus

Companies team up with academics to research treatments for autoimmune disorder

National Institute for Health and Care Excellence NICE logo

Final NICE ‘no’ for J&J’s Stelara in psoriatic arthritis

Committee says drug is more expensive and less effective than TNF alpha inhibitors

- PMLiVE

Pfizer gains ground in cholesterol antibody chase

 Reports positive phase 2b data for its PCSK9 blocker

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links